CD274 and neoplasm: Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis demonstrate clinical efficacy by reversing T cell exhaustion and restoring anti-tumor immune surveillance through blockade of this critical co-inhibitory pathway (36).